NCT01728779View on ClinicalTrials.gov

Stereotactic Body Radiation With Nelfinavir for Oligometastases

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 8, 2014

Primary Completion Date

March 31, 2020

Study Completion Date

December 31, 2020

Conditions
Oligometastases
Interventions
DRUG

Nelfinavir

Commercially available nelfinavir (1250 mg) will be administered orally twice daily for 14 days.

RADIATION

Stereotactic Body Radiation (SBRT)

15 Gy dose (per lesion site) of SBRT will be administered

Trial Locations (1)

21231

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT01728779 - Stereotactic Body Radiation With Nelfinavir for Oligometastases | Biotech Hunter | Biotech Hunter